Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Author(s): Chris Wai Hang Lo , Yue Fei , Bernard Man Yung Cheung Added: 3 years ago

Prevention & Chronic Conditions
Diabetes in Stage C Heart Failure
Author(s): Anjali Agarwalla , Jadry Gruen , Carli Peters , et al Added: 2 years ago

Heart Failure

Prevention & Chronic Conditions
Author(s): Patrick Campbell , Selim Krim , Hector Ventura Added: 3 years ago
Heart failure remains a significant burden to the US healthcare system and contributes greatly to the morbidity and mortality of the population. The impact of an ageing population, improved survival in coronary artery disease (CAD) and adverse life-style choices will ultimately result in an increased burden on an already taxed health care system. Heart failure affects over 5 million people with… View more

Heart Failure

Prevention & Chronic Conditions
SGLT2i in HFpEF
Author(s): Mauro Gori , Emilia D’Elia , Edoardo Sciatti , et al Added: 1 year ago

Heart Failure
Author(s): Juan Tamargo Added: 3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of… View more

Heart Failure
Polypharmacy in Older People With Heart Failure
Author(s): Maria Stefil , Matthew Dixon , Jameela Bahar , et al Added: 1 year ago

Heart Failure
Neprilysin as a Biomarker: Challenges and Opportunities
Author(s): Noemi Pavo , Suriya Prausmüller , Philipp E Bartko , et al Added: 3 years ago
Neprilysin (NEP) was more or less unrecognised by the cardiovascular community until 2014 when the Prospective Comparison of ARNi With ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study reported impressive clinical benefits resulting from the combination of an angiotensin receptor blocker (ARB) with a neprilysin inhibitor (angiotensin receptor… View more

MI/ACS
Author(s): Bao Tran , Gregg C Fonarow Added: 3 years ago
Heart failure (HF) remains a major public health problem resulting in substantial morbidity, mortality and healthcare expenditures globally. The European Society of Cardiology (ESC) 2012 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure and the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 2013 Guideline for the Management of Heart… View more

Standards & Guidelines

Heart Failure
Epicardial Fat in HFpEF: Correlation or Causation?
Author(s): Mary-Tiffany Oduah , Varun Sundaram , Yogesh Reddy Added: 1 year ago

Heart Failure
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 11 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure